

Application No. 10/555,757
Attorney Docket No. 604-756

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Harbige et al.) Group Art Unit: Not yet assigned
Application No.: 10/555,757) Examiner: Not yet assigned
Filed: November 7, 2006)
For: USE OF TRIGLYCERIDE OILS) Confirmation No.: 2532
CONTAINING GAMMA-)
LINOLENIC ACID RESIDUES AND)
LINOLEIC ACID RESIDUES FOR)
THE TREATMENT OF)
NEURODEGENERATIVE)
DISEASE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


DECLARATION UNDER 37 C.F.R. § 1.47 OF MR. PAUL MUSSENDEN

I, PAUL MUSSENDEN, do hereby declare and state as follows:

1. I am Head of Legal at BTG International, Ltd. ("BTG"). I have been employed in my present position for 6 months. Previously, I was Senior Legal Advisor for 6 years.

2. U.S. Application No. 10/555,757 ("the '757 application") lists Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, and Paul Barraclough as inventors.
3. To the best of my knowledge, Ms. Jane Ensor of Howrey LLP, London, England, is the legal representative of Sharief.
4. On March 9, 2007, I telephoned Ms. Ensor and left a message for her to return my call. I followed up with an email on March 12, 2007 (Exhibit A). In my email, I indicated that Sharief was a named inventor on certain patents relating to a potential treatment for multiple sclerosis. I did not mention the need for his execution of the '757 declaration. Rather, I indicated that BTG was interested in contacting Sharief about the project.
5. I informed Ms. Ensor that King's College London, Sharief's former employer, had provided only her contact information to me as a means to reach Sharief. Ms. Ensor replied that she had communicated my message to Sharief, who indicated to her that he would be in contact with me (Exhibit A). Ms. Ensor indicated that she could do no more than to have forwarded my message to Sharief. Sharief did not respond to my message.

I further declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true, and understand that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. 1001), and may jeopardize the enforceability of any patent issuing from the '757 application.

A handwritten signature in black ink, appearing to read "Paul Mussenden", is written over a horizontal line.

Paul Mussenden

4 October 2007

EXHIBIT A

From: Ensor, Jane [mailto:EnsorJ@Howrey.com]
Sent: 12 March 2007 19:03
To: Paul Mussenden
Cc: Tony Dolan; Tariq Osman
Subject: RE: Dr.M.Sharief

Dear Paul

I emailed Dr Sharief on Saturday having picked up your message on Friday evening. Dr Sharief stated that he would contact you, but I will also forward to him your email below.

You will appreciate that I can do nothing more than forward your message to him and it will then be his decision as to when and if he contacts you.

With kind regards.

Jane

From: Paul Mussenden [mailto:paul.mussenden@BTGplc.com]
Sent: 12 March 2007 18:43
To: Ensor, Jane
Cc: Tony Dolan; Tariq Osman
Subject: Dr.M.Sharief

Dear Jane

My name is Paul Mussenden of BTG plc. I called and left a message for you on Friday last week. BTG is a drug development company and we are in the early stages of developing a potential treatment for Multiple Sclerosis. The intellectual property rights supporting this development effort originated from the University of Greenwich and King's College London and Dr. Mohammed Sharief is a named inventor on certain of the patents and has been an important contributor to the project.

BTG is aiming to commence a phase 1 clinical trial of a lead product (BGC20-0134) based on this technology and wishes to contact Dr. Sharief in order to discuss the planned programme of work and to consider whether he would be willing to act as a consultant for us. We believe he could make an important contribution to our efforts.

We have contacted King's College but they would not discuss Dr. Sharief and were not willing to provide us with his contact information. All they were willing to provide were your contact details. We understand that you act for Dr. Sharief. We are not interested in Dr. Sharief's previous, existing or future relationship with Kings and wish to discuss a direct relationship with him.

Please would you pass on our contact details to Dr. Sharief. We would very much like to make contact with him. We would be willing to come into your offices to meet Dr. Sharief to discuss this or in the first instance come in to explain to you more fully our plans. Dr. Sharief previously dealt with my colleague Tariq Osman and if he were to wish to speak to Tariq in the first instance that would obviously be fine. I look forward to hearing from you.

Regards

Paul Mussenden

Email disclaimer

This email and its attachments are confidential and may be legally privileged. This email is intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of BTG PLC or its affiliates.

If you are not the intended recipient: (1) you are kindly requested to return a copy of this message to the sender indicating that you have received it in error, and to destroy the received copy; and (2) any disclosure or distribution of this message, as well as any action taken or omitted to be taken in reliance on its content, is prohibited and may be unlawful.

BTG plc: Registered in England No 2670500 Registered office: 10 Fleet Place, Limeburner Lane, London, EC4M 7SB, UK.

BTG International Limited: Registered in England No 02664412 .Registered office: 10 Fleet Place, Limeburner Lane, London, EC4M 7SB, UK

BTG International Inc. Incorporated in Delaware, USA. Registered office: Five Tower Bridge, 300 Barr Harbor Drive, Suite 800, West Conshohocken, PA 19428-2998, USA
Provensis Ltd. It is registered in England, company number 3694409.

10 Fleet Place, Limeburner Lane, London, EC4M 7SB, UK